Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia December 10, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 3, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD November 26, 2019 • 4:05 PM EST
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference November 25, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia November 21, 2019 • 8:00 AM EST
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder November 20, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering November 20, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights November 8, 2019 • 4:45 PM EST
